Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy | Zendy

J. Pavie | Zendy; Raphaël Porcher | Zendy; Carlo Torti | Zendy; J. Medraño | Zendy; Antonella Castagna | Zendy; Nadia Valin | Zendy; Stefano Rusconi | Zendy; Adriana Ammassari | Zendy; Jade Ghosn | Zendy; Constance Delaugerre | Zendy; JeanMichel Molina | Zendy; Marco Franzetti | Zendy; Caroline LascouxCombes | Zendy; Patrizia Lorenzini | Zendy; Giampiero Carosi | Zendy; Laura Albini | Zendy; P. Nasta | Zendy; Eugenia Quirós-Roldán | Zendy; Filippo Castelnuovo | Zendy; A. Rachline | Zendy

Open Access

Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy

Author(s) -

J. Pavie,

Raphaël Porcher,

Carlo Torti,

J. Medraño,

Antonella Castagna,

Nadia Valin,

Stefano Rusconi,

Adriana Ammassari,

Jade Ghosn,

Constance Delaugerre,

JeanMichel Molina,

Marco Franzetti,

Caroline LascouxCombes,

Patrizia Lorenzini,

Giampiero Carosi,

Laura Albini,

P. Nasta,

Eugenia Quirós-Roldán,

Filippo Castelnuovo,

A. Rachline

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr316

Subject(s) - medicine , atazanavir , abacavir , lamivudine , emtricitabine , stavudine , viral load , hazard ratio , gastroenterology , combination therapy , virology , human immunodeficiency virus (hiv) , hepatitis b virus , antiretroviral therapy , confidence interval , virus

Limited data are available on the use of unboosted atazanavir in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced HIV-infected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research